A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/ refractory FLT3-ITD–mutant acute myeloid leukemia

Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/ refractory FLT3-ITD–mutant acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences